Template:Antiparkinson agents: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
m 1 revision imported |
||
| (One intermediate revision by one other user not shown) | |||
| Line 10: | Line 10: | ||
| group1 = [[Dopamine|DA]] [[Precursor (chemistry)|precursor]]s | | group1 = [[Dopamine|DA]] [[Precursor (chemistry)|precursor]]s | ||
| list1 = | | list1 = | ||
* [[ | * [[Levodopa]]<sup>#</sup> ([[levodopa/benserazide|+benserazide]], [[levodopa/carbidopa|+carbidopa]], [[levodopa/carbidopa/entacapone|+carbidopa/entacapone]]) | ||
* [[Melevodopa]] | * [[Foslevodopa]] ([[foslevodopa/foscarbidopa|+foscarbodipa]]) | ||
* [[Melevodopa]] ([[melevodopa/carbidopa|+carbidopa]]) | |||
| group2 = [[Dopamine receptor|DA receptor]] [[Dopamine agonist|agonist]]s | | group2 = [[Dopamine receptor|DA receptor]] [[Dopamine agonist|agonist]]s | ||
| list2 = | | list2 = | ||
* | * ''Ergoline:'' [[Bromocriptine]] | ||
* [[Cabergoline]] | * [[Cabergoline]] | ||
* [[Dihydroergocryptine]] | * [[Dihydroergocryptine]] | ||
* [[Lisuride]] | * [[Lisuride]] | ||
* [[Pergolide]] | * [[Pergolide]] | ||
* ''Non-ergoline:'' [[Apomorphine]] | |||
* [[Piribedil]] | * [[Piribedil]] | ||
* [[Pramipexole]] | * [[Pramipexole]] | ||
* [[Ropinirole]] | * [[Ropinirole]] | ||
* [[Rotigotine]] | * [[Rotigotine]] | ||
* [[Talipexole]] | |||
| group3 = [[Monoamine oxidase B|MAO-B]] [[Monoamine oxidase inhibitor|inhibitor]]s | | group3 = [[Monoamine oxidase B|MAO-B]] [[Monoamine oxidase inhibitor|inhibitor]]s | ||
| Line 40: | Line 43: | ||
| group5 = [[Aromatic L-amino acid decarboxylase|AAAD]] [[Aromatic L-amino acid decarboxylase inhibitor|inhibitor]]s | | group5 = [[Aromatic L-amino acid decarboxylase|AAAD]] [[Aromatic L-amino acid decarboxylase inhibitor|inhibitor]]s | ||
| list5 = | | list5 = | ||
* [[Benserazide]] | * [[Benserazide]] ([[levodopa/benserazide|+levodopa]]) | ||
* [[Carbidopa]]<sup>#</sup> | * [[Carbidopa]]<sup>#</sup> ([[levodopa/carbidopa|+carbidopa]], [[melevodopa/carbidopa|+melevodopa]], [[levodopa/carbidopa/entacapone|+carbidopa/entacapone]]) | ||
* [[Foscarbidopa]] ([[foslevodopa/foscarbidopa|+foslevodopa]]) | |||
}} | }} | ||
| Line 63: | Line 67: | ||
* [[Procyclidine]] | * [[Procyclidine]] | ||
* [[Profenamine]] | * [[Profenamine]] | ||
* [[Tigloidine]] | |||
* [[Trihexyphenidyl]] | * [[Trihexyphenidyl]] | ||
* [[Tropatepine]] | * [[Tropatepine]] | ||
| Line 68: | Line 73: | ||
| group3 = Others | | group3 = Others | ||
| list3 = | | list3 = | ||
* [[ | * [[Adamantane]]s (e.g., [[amantadine]], [[memantine]], [[rimantadine]])<!-- Controversial and/or off-label --> | ||
* [[Adenosine receptor antagonist]]s (e.g., [[caffeine]], [[istradefylline]])<!-- Caffeine off-label --> | |||
* [[Budipine]] | * [[Budipine]] | ||
| list4 = | | list4 = | ||
| Line 80: | Line 84: | ||
[[Category:Drug templates by ATC]] | [[Category:Drug templates by ATC]] | ||
</noinclude> | </noinclude> | ||
Latest revision as of 17:41, 8 March 2025
| Antiparkinson agents (N04) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
